FDA Approves LEQEMBI IQLIK: First At-Home Injection for Alzheimer’s Maintenance Therapy
The following article discusses the U.S. Food and Drug Administration’s (FDA) recent approval of LEQEMBI® IQLIK™ (lecanemab-irmb), a new subcutaneous injection option for the maintenance treatment of early Alzheimer’s disease. […]
FDA Approves LEQEMBI IQLIK: First At-Home Injection for Alzheimer’s Maintenance Therapy Read More »
